Biotech Startups

GeneCker develops CRISPR/Cas9-based liquid biopsy diagnostics for early cancer detection, analyzing low-frequency circulating tumor DNA (ctDNA) mutations in blood. The company serves the in vitro diagnostics market with ultra-sensitive genomic testing for precision cancer diagnosis.

2 investors

Cellusion is a regenerative medicine company developing innovative technologies and products based on patient-centric research across disease areas where regenerative medicine can create new therapeutic value.

2 investors

Digital Blast develops satellite and space technology solutions. The company supports Japan's space industry through workforce development initiatives in partnership with non-profit organizations.

2 investors

Reprocell is a biotechnology company that manufactures and sells iPS cell-related research reagents, provides drug discovery support services including iPS cell establishment and CRO services, and offers clinical testing and regenerative medicine product development.

2 investors

10x Science provides an AI platform that automates protein characterization for drug developers, reducing months of manual analysis to speed the evaluation of therapeutic candidates in early-stage development.

2 investors

20/20 BioLabs develops AI-powered blood tests for early detection of multiple cancers and chronic diseases, using protein tumor markers and machine learning. The company offers affordable, at-home collection tests starting under $200, targeting individuals and healthcare providers seeking early disease detection.

2 investors

35Pharma is a biopharmaceutical company developing biologics to treat diseases with high unmet medical need. The company combines scientific expertise with operational efficiency to advance complex therapies from early discovery through clinical validation.

2 investors

3Dnamics engineers 3D organoid models from human stem cells to develop therapeutics for neurological diseases including Alzheimer's and Parkinson's. The company serves pharmaceutical and biotech research sectors developing novel treatments.

2 investors

4G Clinical builds technology and delivery services aimed at reducing avoidable delay in clinical trial execution, serving sponsors, CROs, and research sites. The company works within the clinical research and clinical trial supply space to help therapies reach patients faster.

2 investors

4TEEN4 develops monoclonal antibody therapeutics targeting shock and critical illness in patients. The company is advancing invobenitug (procizumab), a first-in-class treatment designed to address circulating dipeptidyl peptidase 3, a molecular driver of cardiovascular dysfunction and organ failure in shock states.

2 investors

5AM Ventures is an investment firm with professionals holding expertise in science, medicine, operations, legal, and finance who identify and develop life science portfolio companies.

2 investors

64x provides a platform and product suite for manufacturing advanced therapeutics, including gene therapies, cell therapies, and biologics. The company uses massively parallelized screening and computational insights to engineer high-yield cell lines and production technologies that accelerate the manufacturing of next-generation medicines.

2 investors

83 Sciences converts unpublished experimental research data into academic papers, patents, and commercialization opportunities for research organizations. The platform captures laboratory data and uses AI to identify valuable findings within discarded experimental datasets.

2 investors

A51 develops a technology platform for programming RNA molecules to control cell behavior. The company operates in the biotech/synthetic biology sector.

2 investors

Abbelight provides microscopy equipment, reagents, and services to researchers and biotech labs for studying biology at the molecular level. The company develops bioimaging platforms intended to support advanced diagnostics and therapeutics.

2 investors

AbbraTech develops a platform technology for the discovery, engineering, and validation of antibodies, targeting disease-relevant proteins that are difficult to address with conventional approaches. It works with industry and academic partners to develop antibody therapies for conditions such as cancer, immune disorders, and viral infections.

2 investors

Abingdon Health is a contract developer and manufacturer of rapid lateral flow diagnostic tests, serving healthcare, animal health, and plant health sectors. It provides services from biomarker validation through FDA submission, scale-up, and large-scale manufacturing, and also supplies its own lateral flow test brands to consumers, retail, wholesale, and distributors globally.

2 investors

ABL Bio develops biotherapeutic drugs using dual antibody platform technology for immunotherapy cancer treatments and degenerative neurological diseases. The company is a South Korea-based biotech research firm with proprietary platforms designed to treat intractable diseases.

2 investors

Abselion develops measurement tools and a platform combining hardware, purpose-built assay formats, and software for biological measurements such as protein quantification. It serves scientists and researchers across life sciences, biotech, and therapeutic development.

2 investors

Absolute Foods is an agricultural biotechnology company working on bioscience-based approaches to farming and sustainability. The page references work in gene editing, agrobacterium biology, and biological crop protection, positioning the company in the ag-tech and bio-innovation space with a stated focus on building a global company from India.

2 investors

Eagle Pharmaceuticals develops and commercializes specialty pharmaceutical products for acute care and oncology, including injectable medications for procedural sedation, chemotherapy, lymphomas, and malignant hyperthermia management.

2 investors

Access Vascular develops thrombus-evading intravascular catheters made from a proprietary biomaterial, offering an FDA-cleared PICC and the HydroMID peripherally inserted midline catheter to reduce vascular access complications. The company designs and manufactures its medical devices for clinical use in the United States.

2 investors

Accipiter Biosciences uses computational protein design to develop de novo, single-agent protein therapies that engage multiple cell-surface receptors at once, functioning as agonists. Its platform targets complex conditions such as autoimmune disorders and cancer as an alternative to traditional combination therapies.

2 investors

Accuitis is developing a lead drug compound that restores mitochondrial SIRT3 expression to recover healthy cellular function, targeting neurodegenerative diseases including Alzheimer's, Parkinson's, and methamphetamine addiction. Its work is in preclinical research and development.

2 investors